Lacey E. Dobrolecki

Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy.

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.

A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.

Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.

Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.

C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.

Chromosome 12p Amplification in Triple-Negative/Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.